Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here.
  Pharmaceutical Technology Europe E-Alert
 
28 September 2012

IN THIS ISSUE
Sanofi Job Cuts
R&D in China
EMA Streamlining
Watson recall
Twitter

 
Sanofi to Cut 900 Jobs
Sanofi has announced that it will be shedding approximately 900 jobs in France in the lead up to 2015 as it seeks to implement certain key strategic objectives. More...
 
Novo Nordisk Expands R&D Facility in China
Novo Nordisk has invested $100 million in expanding its research centre in Beijing, China, to 12000 m2. More...
 
EMA Streamlines Working Parties
The European Medicines Agency (EMA) has abolished its Cell-based Product Working Party (CPWP) and Gene Therapy Working Party (GTWP), with the aim of improving efficiencies and optimising the use of available expertise. More...
 
Watson Issues Recall of Combination Painkiller
Watson Laboratories has issued a recall in the US for two lots of hydrocodone bitartrate and acetaminophen tablets, which are indicated for the relief of moderate to moderately severe pain. More...
 
Get the Latest Updates on Twitter
We regularly tweet the latest news and rumours hitting the web about the pharmaceutical industry. Follow us to keep up to date. More...
Key Topics:

Latest blog posts
CMS Trouble? Send us Your Questions
Budget Policies Jeopardize FDA Funding and User Fees
Why Sanofi's Recent Job Cuts Could be Worse
More blog posts

Latest articles
Process Analytical Technology: Charting Progress in Data Analysis
Future Innovation in Drug Delivery
Pre-use Filter-Integrity Testing: To Test or Not To Test?
More articles

Upcoming events
CPhI Worldwide (9–11 October | Spain)
2012 AAPS (14–18 October | USA)
Virus and TSE Safety Made Simple (30–31 October | Germany)
More events

Products/Service Profiles
Agilent

Realize Effective Pharmaceuticals
Reliable solutions enable pharmaceutical scientists to innovate in disease research, accelerate drug discovery and have greater confidence throughout development and manufacturing. Agilent solutions in genomics research, automation, separation and detection technologies along with workflow driven software solutions helps deliver the answers to bring effective therapeutics to market.
Learn more at www.agilent.com/lifesciences/realizepharma

 
Agilent

Agilent ICP-MS/ICP-OES
Reliable solutions for regulated pharmaceutical laboratories

Complying with new elemental impurity limits as defined by draft USP methods <232>/<233> could pose a significant challenge. You need to choose qualified hardware and software, ensure verification, and maintain electronic records. But there is a simple answer – Request a free copy of our primer on Elemental Impurity Analysis to learn more

 
BASF SE, G-ENP/K

Making ibuprofen faster for 20 years.
Faster processes: Ibuprofen DC 85 reduces production time and costs. Faster acting: Ibuprofen Sodium & Racemic Ibuprofen Lysinate take effect faster than conventional ibuprofen. Read more

 
Powder Systems Ltd

PSL's agitated nutsche filter dryers are designed by process experts for optimum levels of performance, safety and quality. PSL's high containment gloveboxes can be incorporated for the safe handling of highly potent APIs. Read more

 
Tosoh

TOYOPEARL® MX-Trp-650M Mixed-Mode Resin
TOYOPEARL MX-Trp-650M is a new multimodal cation exchange resin with unique selectivity and high recovery. It provides high protein binding capacities and tolerates high conductivity feedstocks. Read more


Event Profile
Perkin Elmer

3 Live Webinars coming soon.
Supply chain security - how best to use the most important tool in supply chain protection
Infrared spectroscopy is the most economical way to screen against many of the risks that exist today in your supply chain of raw materials – counterfeit, contaminated, adulterated, diluted, substituted, false claims of purity/source etc.
Read more

 

Pharma Integrates 2012
Nov 28-29 2012
London, UK
Where do you see partnerships strategically?
This is the central question that Pharma Integrates 2012 (PI2012) will tackle. PI2012 is the exclusive retreat for the bio/pharmaceutical procurement and outsourcing elite.
Read more

 
Survey
What do you think will be the greatest benefit of FDA's Generic Drug User Fees Amendments of 2012 (GDUFA)?
 
It will accelerate application review times 53%
 
 
It will increase the number of foreign inspections 26%
     
 
It will increase the transparency of manufacturing sites 21%

This week we would like to know...

The European Generic Medicines Agency has recently claimed that the potential fees to be charged by the European Medicines Agency for pharmacovigilance activities are unjustifiably high. Do you agree?

Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.